Yang Feng-qiang, Zhang Hai-Min, Chen Shao-Jun, Yan Yang, Zheng Jun-hua
Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
PLoS One. 2015 Mar 20;10(3):e0120258. doi: 10.1371/journal.pone.0120258. eCollection 2015.
Some microRNAs (miRNAs) are abnormally expressed in cancer and contribute to tumorigenesis. In the present study, we investigated the role of miR-506 in clear cell renal cell carcinoma (ccRCC).
miR-506 expression was detected in renal cancer cell lines 786-O, ACHN, Caki-1, and Caki-2 and ccRCC specimens by quantitative real-time-PCR. We assessed the association of miR-506 expression with pathology and prognosis in ccRCC patients. We over-expressed and knocked-down miR-506 expression in two renal cancer cell lines, 786-O and ACHN, and assessed the impact on cell proliferation, migration and invasion. A luciferase reporter assay was conducted to confirm the target gene of miR-506 in renal cancer cell lines.
miR-506 was significantly down-regulated in renal cancer cell lines and ccRCC specimens. Low miR-506 expression in ccRCC specimens was associated with an advanced clinical stage and poor prognosis. miR-506 expression was an independent prognostic marker of overall ccRCC patient survival in a multivariate analysis. Over-expression of miR-506 in renal cancer cells decreased cell growth and metastasis, In contrast, down-regulation of miR-506 expression promoted renal cancer cell growth and metastasis. FLOT1, a potential target gene of miR-506, was inversely correlated with miR-506 expression in ccRCC tissues. Consistent with the effect of miR-506, knockdown of FLOT1 by siRNA inhibited cell malignant behaviors. Rescue of FLOT1 expression partially restored the effects of miR-506.
miR-506 exerts its anti-cancer function by directly targeting FLOT1 in renal cancer, indicating a potential novel therapeutic role in renal cancer treatment.
一些微小RNA(miRNA)在癌症中异常表达并促进肿瘤发生。在本研究中,我们调查了miR-506在透明细胞肾细胞癌(ccRCC)中的作用。
通过定量实时PCR检测肾癌细胞系786-O、ACHN、Caki-1和Caki-2以及ccRCC标本中miR-506的表达。我们评估了miR-506表达与ccRCC患者病理及预后的相关性。我们在两种肾癌细胞系786-O和ACHN中过表达和敲低miR-506表达,并评估其对细胞增殖、迁移和侵袭的影响。进行荧光素酶报告基因检测以确认肾癌细胞系中miR-506的靶基因。
miR-506在肾癌细胞系和ccRCC标本中显著下调。ccRCC标本中miR-506低表达与临床分期晚期及预后不良相关。在多变量分析中,miR-506表达是ccRCC患者总体生存的独立预后标志物。肾癌细胞中miR-506过表达降低细胞生长和转移,相反,miR-506表达下调促进肾癌细胞生长和转移。FLOT1是miR-506的潜在靶基因,在ccRCC组织中与miR-506表达呈负相关。与miR-506的作用一致,siRNA敲低FLOT1抑制细胞恶性行为。FLOT1表达的挽救部分恢复了miR-506的作用。
miR-506通过直接靶向肾癌细胞中的FLOT1发挥其抗癌功能,表明在肾癌治疗中具有潜在的新治疗作用。